molindone (moban) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Molindone (Moban) is a therapeutic antipsychotic, used in the treatment of schizophrenia. The exact mechanism has not been established, however, based on electroencephalogram (EEG) studies, molindone is thought to act by occupying (antagonizing) dopamine (D2) receptor sites in the reticular limbic systems in the brain, thus decreasing dopamine activity. Decreased dopamine activity results in decreased physiological effects normally induced by excessive dopamine stimulation, such as those typically seen in manifestations of psychotic disorders. The side effect profile of molindone is similar to that of other typical antipsychotics. Unlike most antipsychotics, however, molindone use is associated with weight loss.   NCATS

Chemistry

  • SMILES: CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2
  • InChIKey: KLPWJLBORRMFGK-UHFFFAOYSA-N
  • Mol. Mass: 276.38
  • ALogP: 1.96
  • ChEMBL Molecules:
    molindone  
    molindone hydrochloride  
More Chemistry

Pharmacology

Alternative names

en-1733a | moban | molindona | molindone | (+-)-molindone | (+/-)-molindone | molindone hcl | molindone hydrochloride | molindone monohydrochloride | molindonum | spn-810

Organizations (10)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Schizophrenia (approved 1974)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Attention Deficit and Disruptive Behavior Disorders (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 2)

Conduct Disorder (Phase 2)

Schizophrenia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue